Fairmount Funds Management LLC
- SEC CIK
- 0001802528
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 9, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 26
- −1 vs. Q2 2022
- Portfolio value
- $542.1M
- +$105.2M (+24.1%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AXSMAxsome Therapeutics, Inc. | COM | 1,896,647 | $84.6M | 15.6% | +954,076+101.2% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 2,758,975 | $41.2M | 7.6% | 00.0% | Unchanged | History |
| NUVLNuvalent, Inc. | COM | 2,079,863 | $40.4M | 7.5% | +364,345+21.2% | Added | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 2,543,107 | $32.0M | 5.9% | −800,000−23.9% | Reduced | History |
| BHVNBiohaven Ltd. | COM | 204,743 | $31.0M | 5.7% | −59,463−22.5% | Reduced | History |
| NBIXNeurocrine Biosciences Inc | Stock | 283,000 | $30.1M | 5.5% | 00.0% | Unchanged | History |
| INSMINSMED Inc | COM PAR $.01 | 1,336,368 | $28.8M | 5.3% | +10,000+0.8% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,369,623 | $28.1M | 5.2% | +425,531+45.1% | Added | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 2,678,982 | $27.4M | 5.1% | +1,752,380+189.1% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 73,526 | $26.0M | 4.8% | 00.0% | Unchanged | History |
| ENTAEnanta Pharmaceuticals Inc | COM | 469,264 | $24.3M | 4.5% | 00.0% | Unchanged | History |
| PNTPOINT Biopharma Global Inc. | COM | 2,833,950 | $21.9M | 4.0% | +1,000,000+54.5% | Added | History |
| ANNXAnnexon, Inc. | COM | 3,358,563 | $20.8M | 3.8% | +465,963+16.1% | Added | History |
| DBVTDBV Technologies S.A. | SPONSORED ADR | 7,064,964 | $12.5M | 2.3% | +2,233,809+46.2% | Added | History |
| TYRATyra Biosciences, Inc. | COM | 1,416,998 | $12.5M | 2.3% | 00.0% | Unchanged | History |
| ACADAcadia Pharmaceuticals Inc | COM | 751,804 | $12.3M | 2.3% | 00.0% | Unchanged | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 2,050,000 | $12.1M | 2.2% | +2,050,000 | New | History |
| ONCBeOne Medicines Ltd. | ADR | 86,400 | $11.6M | 2.1% | −25,000−22.4% | Reduced | History |
| KROSKeros Therapeutics, Inc. | COM | 272,498 | $10.3M | 1.9% | 00.0% | Unchanged | History |
| TRVITrevi Therapeutics, Inc. | COM | 5,696,515 | $8.77M | 1.6% | +4,072,126+250.7% | Added | History |
| ATXSAstria Therapeutics, Inc. | COM | 911,736 | $8.24M | 1.5% | 00.0% | Unchanged | History |
| AMRNAmarin Corp PLC | SPONS ADR NEW | 5,584,837 | $6.09M | 1.1% | 00.0% | Unchanged | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 389,588 | $3.73M | 0.7% | 00.0% | Unchanged | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 1,231,566 | $3.40M | 0.6% | −1,437,734−53.9% | Reduced | History |
| TILInstil Bio, Inc. | COM | 673,905 | $3.26M | 0.6% | 00.0% | Unchanged | History |
| ALLKAllakos Inc. | COM | 147,189 | $901.0K | 0.2% | 00.0% | Unchanged | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| Axsome Therapeutics Inc05464T904 | CALL | – | $26.8M |
Sold out since Q2 2022 (2)
Positions held at the end of Q2 2022 that are gone from this filing.